Medical cannabis company goes public – Cantourage listed in Scale Segment

A team led by Dr. Thorsten Kuthe advised Cantourage Group SE (“Cantourage”) on its listing in Frankfurt Stock Exchange’s Scale Segment where the company’s entire share capital is traded. The free float of 15% corresponds to two million shares. Cantourage’s shares have been listed since November 11. Hauck Aufhäuser Investment Banking acted as the company’s exclusive financial advisor and listing agent.

Cantourage is a leader in the production of medical cannabis in Europe and the UK, generating revenue of EUR 5 million in 2021. It intends to triple its revenue in 2022. The company offers solutions in all relevant market segments and at every stage of the value creation process. Cantourage aims to improve access to innovative medical cannabis products and cooperates with global leaders in production, manufacturing, and logistics as well as with wholesalers and pharmacies.

Last year, Germany was the European country with the highest number of medical cannabis patients.

Counsel to Cantourage Group SE
Heuking Kühn Lüer Wojtek:
Dr. Thorsten Kuthe (Lead),
Meike Dresler-Lenz,
Christopher Görtz,
Tatiana Vorotnitskaya (all Stocks and Capital Markets), Cologne